{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:45:11Z","timestamp":1790163911736,"version":"4.1.0"},"reference-count":91,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Lassa virus (LASV), which causes considerable morbidity and mortality annually, has a high genetic diversity across West Africa. LASV glycoprotein (GP) expresses this diversity, but most LASV vaccine candidates utilize only the Lineage IV LASV Josiah strain GP antigen as an immunogen and homologous challenge with Lineage IV LASV. In addition to the sequence variation amongst the LASV lineages, these lineages are also distinguished in their presentations. Inter-lineage variations within previously mapped B-cell and T-cell LASV GP epitopes and the breadth of protection in LASV vaccine\/challenge studies were examined critically. Multiple alignments of the GP primary sequence of strains from each LASV lineage showed that LASV GP has diverging degrees of amino acid conservation within known epitopes among LASV lineages. Conformational B-cell epitopes spanning different sites in GP subunits were less impacted by LASV diversity. LASV GP diversity should influence the approach used for LASV vaccine design. Expression of LASV GP on viral vectors, especially in its prefusion configuration, has shown potential for protective LASV vaccines that can overcome LASV diversity. Advanced vaccine candidates should demonstrate efficacy against all LASV lineages for evidence of a pan-LASV vaccine.<\/jats:p>","DOI":"10.3390\/v12040386","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T10:29:38Z","timestamp":1585650578000},"page":"386","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Inter-Lineage Variation of Lassa Virus Glycoprotein Epitopes: A Challenge to Lassa Virus Vaccine Development"],"prefix":"10.3390","volume":"12","author":[{"given":"Francis Ifedayo","family":"Ibukun","sequence":"first","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,31]]},"reference":[{"key":"ref_1","unstructured":"(2018, November 30). Lassa Fever. Available online: http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lassa-fever."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1863-2378.2012.01469.x","article-title":"Lassa fever in West Africa: Evidence for an expanded region of endemicity","volume":"59","author":"Sogoba","year":"2012","journal-title":"Zoonoses Public Health"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Fichet-Calvet, E., and Rogers, D.J. (2009). Risk maps of lassa fever in West Africa. PLoS Negl. Trop. Dis., 3.","DOI":"10.1371\/journal.pntd.0000388"},{"key":"ref_4","first-page":"1","article-title":"Lassa fever in West African sub-region: An overview","volume":"44","author":"Ogbu","year":"2007","journal-title":"J. Vector Borne Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/trstmh\/trv047","article-title":"Mapping the zoonotic niche of Lassa fever in Africa","volume":"109","author":"Mylne","year":"2015","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_6","unstructured":"WHO (2018). Lassa Fever Research and Development (R&D) Roadmap Draft, WHO."},{"key":"ref_7","unstructured":"Nigeria Centre for Disease Control (NCDC) (2019). 2019 Lassa Fever Outbreak Situation Report. Epi Week 50, Nigeria Centre for Disease Control (NCDC)."},{"key":"ref_8","unstructured":"Nigeria Centre for Disease Control (NCDC) (2020). Lassa Fever Situation Report. Epi.Week 07, Nigeria Centre for Disease Control (NCDC)."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/infdis\/155.3.437","article-title":"A prospective study of the epidemiology and ecology of Lassa fever","volume":"155","author":"McCormick","year":"1987","journal-title":"J. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1080\/20477724.2017.1369643","article-title":"Understanding the cryptic nature of Lassa fever in West Africa","volume":"111","author":"Gibb","year":"2017","journal-title":"Pathog. Glob. Health"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"25280","DOI":"10.1038\/srep25280","article-title":"New hosts of the Lassa virus","volume":"6","author":"Olayemi","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.cell.2015.07.020","article-title":"Clinical sequencing uncovers origins and evolution of Lassa virus","volume":"162","author":"Andersen","year":"2015","journal-title":"Cell"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lo Iacono, G., Cunningham, A.A., Fichet-Calvet, E., Garry, R.F., Grant, D.S., Khan, S.H., Leach, M., Moses, L.M., Schieffelin, J.S., and Shaffer, J.G. (2015). Using modelling to disentangle the relative contributions of zoonotic and anthroponotic transmission: The case of Lassa fever. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003398"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.1128\/JVI.74.15.6992-7004.2000","article-title":"Genetic diversity among Lassa virus strains","volume":"74","author":"Bowen","year":"2000","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3389\/fmicb.2015.01037","article-title":"Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage","volume":"6","author":"Manning","year":"2015","journal-title":"Front. Microbiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3201\/eid2403.171905","article-title":"New lineage of Lassa virus, Togo, 2016","volume":"24","author":"Whitmer","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e00929-19","DOI":"10.1128\/JVI.00929-19","article-title":"Phylogeography of Lassa virus in Nigeria","volume":"93","author":"Ehichioya","year":"2019","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S1473-3099(19)30486-4","article-title":"Lassa virus circulating in Liberia: A retrospective genomic characterisation","volume":"19","author":"Wiley","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.3201\/eid2510.180523","article-title":"Lassa virus in Pygmy Mice, Benin, 2016\u20132017","volume":"25","author":"Yadouleton","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1128\/iai.37.2.771-778.1982","article-title":"Pathogenesis of Lassa virus infection in guinea pigs","volume":"37","author":"Jahrling","year":"1982","journal-title":"Infect. Immun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1016\/j.vaccine.2007.02.038","article-title":"A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity","volume":"25","author":"Carrion","year":"2007","journal-title":"Vaccine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/0300985816677153","article-title":"Temporal progression of lesions in guinea pigs infected with Lassa virus","volume":"54","author":"Bell","year":"2016","journal-title":"Vet. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Safronetz, D., Mire, C., Rosenke, K., Feldmann, F., Haddock, E., Geisbert, T., and Feldmann, H. (2015). A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003736"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(87)90767-7","article-title":"Vaccinia recombinant expressing lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever","volume":"330","author":"Clegg","year":"1987","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/infdis\/jit004","article-title":"A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques","volume":"207","author":"Safronetz","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S1473-3099(18)30121-X","article-title":"Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: A retrospective, observational cohort study","volume":"18","author":"Okokhere","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.16989.1","article-title":"Lassa virus diversity and feasibility for universal prophylactic vaccine","volume":"8","author":"Lukashevich","year":"2019","journal-title":"F1000Research"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1128\/JCM.00170-17","article-title":"Laboratory diagnosis of Lassa fever","volume":"55","author":"Raabe","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/sj.embor.7400002","article-title":"Identification of Lassa virus glycoprotein signal peptide as a trans-acting maturation factor","volume":"4","author":"Eichler","year":"2003","journal-title":"EMBO Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1743-422X-3-41","article-title":"The role of single N-glycans in proteolytic processing and cell surface transport of the Lassa virus glycoprotein GP-C","volume":"3","author":"Eichler","year":"2006","journal-title":"Virol. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1128\/JVI.00024-12","article-title":"Molecular characterization of the processing of arenavirus envelope glycoprotein precursors by subtilisin kexin isozyme-1\/site-1 protease","volume":"86","author":"Burri","year":"2012","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1126\/science.aam7260","article-title":"Structural basis for antibody-mediated neutralization of Lassa virus","volume":"356","author":"Hastie","year":"2017","journal-title":"Science"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Li, S., Sun, Z., Pryce, R., Parsy, M.-L., Fehling, S.K., Schlie, K., Siebert, C.A., Garten, W., Bowden, T.A., and Strecker, T. (2016). Acidic pH-induced conformations and LAMP1 binding of the lassa virus glycoprotein spike. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005418"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e02063-14","DOI":"10.1128\/mBio.02063-14","article-title":"Arenavirus stable signal peptide is the keystone subunit for glycoprotein complex organization","volume":"5","author":"Bederka","year":"2014","journal-title":"mBio"},{"key":"ref_35","first-page":"52","article-title":"Lassa virus glycoprotein: Stopping a moving target","volume":"31","author":"Hastie","year":"2018","journal-title":"Virus Struct. Expr. Viral Evol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Sommerstein, R., Flatz, L., Remy, M.M., Malinge, P., Magistrelli, G., Fischer, N., Sahin, M., Bergthaler, A., Igonet, S., and Ter Meulen, J. (2015). Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005276"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Bonhomme, C.J., Knopp, K.A., Bederka, L.H., Angelini, M.M., and Buchmeier, M.J. (2013). LCMV glycosylation modulates viral fitness and cell tropism. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0053273"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cell.2019.07.020","article-title":"Convergent structures illuminate features for germline antibody binding and pan-lassa virus neutralization","volume":"178","author":"Hastie","year":"2019","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/bioinformatics\/btu033","article-title":"RAxML version 8: A tool for phylogenetic analysis and post-analysis of large phylogenies","volume":"30","author":"Stamatakis","year":"2014","journal-title":"Bioinformatics"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Miller, M.A., Pfeiffer, W., and Schwartz, T. (2010, January 14). Schwartz creating the CIPRES science gateway for inference of large phylogenetic trees. Proceedings of the 2010 Gateway Computing Environments Workshop (GCE), New Orleans, LA, USA.","DOI":"10.1109\/GCE.2010.5676129"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"vey016","DOI":"10.1093\/ve\/vey016","article-title":"Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10","volume":"4","author":"Suchard","year":"2018","journal-title":"Virus Evol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41541-018-0049-5","article-title":"Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development","volume":"3","author":"Hallam","year":"2018","journal-title":"NPJ Vaccines"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1128\/JVI.01948-08","article-title":"Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys","volume":"83","author":"Baize","year":"2009","journal-title":"J. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.2147\/DDDT.S147276","article-title":"Current research for a vaccine against Lassa hemorrhagic fever virus","volume":"12","author":"Warner","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/nm.4396","article-title":"Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever","volume":"23","author":"Mire","year":"2017","journal-title":"Nat. Med."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Geisbert, T.W., Jones, S., Fritz, E.A., Shurtleff, A.C., Geisbert, J.B., Liebscher, R., Grolla, A., Str\u00f6her, U., Fernando, L., and Daddario, K.M. (2005). Development of a new vaccine for the prevention of Lassa fever. PLoS Med., 2.","DOI":"10.1371\/journal.pmed.0020183"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1128\/JVI.74.15.6777-6783.2000","article-title":"Effective vaccine for Lassa fever","volume":"74","author":"Hutwagner","year":"2000","journal-title":"J. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.virol.2003.12.013","article-title":"Old and new world arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones","volume":"321","author":"Badusche","year":"2004","journal-title":"Virology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"8351","DOI":"10.1128\/JVI.00896-06","article-title":"Identification of protective Lassa virus epitopes that are restricted by HLA-A2","volume":"80","author":"Botten","year":"2006","journal-title":"J. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1038\/s41467-018-06741-w","article-title":"Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever","volume":"9","author":"Hagen","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"eaaw3163","DOI":"10.1126\/scitranslmed.aaw3163","article-title":"Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot","volume":"11","author":"Mateo","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.antiviral.2016.08.012","article-title":"Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies","volume":"133","author":"Cross","year":"2016","journal-title":"Antivir. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"11544","DOI":"10.1038\/ncomms11544","article-title":"Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits","volume":"7","author":"Robinson","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e00189-18","DOI":"10.1128\/mSphere.00189-18","article-title":"Antibodies to the glycoprotein GP2 subunit cross-react between old and new world arenaviruses","volume":"3","author":"Amanat","year":"2018","journal-title":"mSphere"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1099\/0022-1317-72-3-549","article-title":"Antigenic relatedness between arenaviruses defined at the epitope level by monoclonal antibodies","volume":"72","author":"Ruo","year":"1991","journal-title":"J. Gen. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1128\/JCM.01891-10","article-title":"Current molecular epidemiology of Lassa virus in Nigeria","volume":"49","author":"Ehichioya","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0042-6822(89)90287-0","article-title":"Nucleotide sequence of the Lassa virus (Josiah strain) S genome RNA and amino acid sequence comparison of the N and GPC proteins to other arenaviruses","volume":"168","author":"Auperin","year":"1989","journal-title":"Virology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.virol.2003.09.009","article-title":"Sequence analysis of L RNA of Lassa virus","volume":"318","author":"Vieth","year":"2004","journal-title":"Virology"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Safronetz, D., Sogoba, N., Lopez, J.E., Maiga, O., Dahlstrom, E., Zivcec, M., Feldmann, F., Haddock, E., Fischer, R.J., and Anderson, J.M. (2013). Geographic distribution and genetic characterization of Lassa virus in Sub-Saharan Mali. PLoS Negl. Trop. Dis., 7.","DOI":"10.1371\/journal.pntd.0002582"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/j.jmb.2018.01.013","article-title":"EzMol: A web server wizard for the rapid visualization and image production of protein and nucleic acid structures","volume":"430","author":"Reynolds","year":"2018","journal-title":"J. Mol. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/bioinformatics\/btp033","article-title":"Jalview version 2\u2014A multiple sequence alignment editor and analysis workbench","volume":"25","author":"Waterhouse","year":"2009","journal-title":"Bioinforma. Oxf. Engl."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e00039-20","DOI":"10.1128\/mBio.00039-20","article-title":"A Lassa fever live-attenuated vaccine based on codon deoptimization of the viral glycoprotein gene","volume":"11","author":"Cai","year":"2020","journal-title":"mBio"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4103\/2277-9175.166137","article-title":"In silico prediction of B- and T- cell epitope on Lassa virus proteins for peptide based subunit vaccine design","volume":"4","author":"Verma","year":"2015","journal-title":"Adv. Biomed. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s13205-018-1106-5","article-title":"Design of peptide-based epitope vaccine and further binding site scrutiny led to groundswell in drug discovery against Lassa virus","volume":"8","author":"Hossain","year":"2018","journal-title":"3 Biotech"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"417","DOI":"10.6026\/97320630013417","article-title":"Computer aided epitope design as a peptide vaccine component against Lassa virus","volume":"13","author":"Faisal","year":"2017","journal-title":"Bioinformation"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Sullivan, B.M., Sakabe, S., Hartnett, J.N., Ngo, N., Goba, A., Momoh, M., Demby Sandi, J., Kanneh, L., Cubitt, B., and Garcia, S.D. (2020). High crossreactivity of human T cell responses between Lassa virus lineages. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008352"},{"key":"ref_67","first-page":"1223","article-title":"Lassa fever virus peptides predicted by computational analysis induce epitope-specific cytotoxic-T-lymphocyte responses in HLA-A2.1 transgenic mice","volume":"12","author":"Boesen","year":"2005","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_68","unstructured":"WHO (2017). Target Product Profile for Lassa Virus Vaccine, WHO."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"13934","DOI":"10.1128\/JVI.79.22.13934-13942.2005","article-title":"A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses","volume":"79","author":"Lukashevich","year":"2005","journal-title":"J. Virol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1016\/j.vaccine.2008.07.057","article-title":"Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates","volume":"26","author":"Lukashevich","year":"2008","journal-title":"Vaccine"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1128\/JVI.74.5.2186-2192.2000","article-title":"Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein","volume":"74","author":"Badusche","year":"2000","journal-title":"J. Virol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1016\/j.vaccine.2019.07.023","article-title":"A vaccine based on recombinant modified Vaccinia Ankara containing the nucleoprotein from Lassa virus protects against disease progression in a guinea pig model","volume":"37","author":"Kennedy","year":"2019","journal-title":"Vaccine"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0042-6822(89)90525-4","article-title":"Protection of guinea pigs from lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of lassa virus","volume":"171","author":"Morrison","year":"1989","journal-title":"Virology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"11677","DOI":"10.1128\/JVI.75.23.11677-11685.2001","article-title":"Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola Viruses","volume":"75","author":"Pushko","year":"2001","journal-title":"J. Virol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.4049\/jimmunol.180.5.3113","article-title":"Absence of CTL responses to early viral antigens facilitates viral persistence","volume":"180","author":"Schildknecht","year":"2008","journal-title":"J. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"11734","DOI":"10.1128\/JVI.01613-15","article-title":"The nucleoprotein is required for lymphocytic choriomeningitis virus-based vaccine vector immunogenicity","volume":"89","author":"Darbre","year":"2015","journal-title":"J. Virol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e01896-18","DOI":"10.1128\/mBio.01896-18","article-title":"Immune-mediated systemic vasculitis as the proposed cause of sudden-onset sensorineural hearing loss following lassa virus exposure in cynomolgus macaques","volume":"9","author":"Cashman","year":"2018","journal-title":"mBio"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1080\/21645515.2019.1616499","article-title":"Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1080\/21645515.2017.1356500","article-title":"A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever","volume":"13","author":"Cashman","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa1804498","article-title":"Genomic analysis of Lassa virus during an increase in cases in Nigeria in 2018","volume":"379","author":"Siddle","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1586\/erv.12.139","article-title":"The search for animal models for Lassa fever vaccine development","volume":"12","author":"Lukashevich","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1126\/science.351.6268.16","article-title":"Unfilled Vials","volume":"351","author":"Cohen","year":"2016","journal-title":"Science"},{"key":"ref_83","unstructured":"(2019, November 07). Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers-Full Text View-ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03805984."},{"key":"ref_84","unstructured":"(2019, November 07). Dose-Ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana-Full Text View-ClinicalTrials, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04093076."},{"key":"ref_85","unstructured":"(2019, November 07). A Trial to Evaluate the Optimal Dose of MV-LASV-Full Text View-ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04055454."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Cross, R.W., Xu, R., Matassov, D., Hamm, S., Latham, T.E., Gerardi, C.S., Nowak, R.M., Geisbert, J.B., Ota-Setlik, A., and Agans, K.N. (2019). Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death. J. Clin. Investig., 130.","DOI":"10.1172\/JCI131958"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.vaccine.2017.12.046","article-title":"Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins","volume":"36","author":"Wang","year":"2018","journal-title":"Vaccine"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1128\/JVI.03035-13","article-title":"Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate","volume":"88","author":"Zapata","year":"2014","journal-title":"J. Virol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/S0140-6736(18)32488-7","article-title":"Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: A double-blind, randomised, placebo-controlled and active-controlled phase 2 trial","volume":"392","author":"Reisinger","year":"2018","journal-title":"Lancet"},{"key":"ref_90","first-page":"22","article-title":"Correlates of GLA family adjuvants\u2019 activities","volume":"39","author":"Reed","year":"2018","journal-title":"Immune Correl. Vaccine Adjuv. Immunogenicity Effic. Infect. Dis. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1128\/JVI.03337-14","article-title":"Synthetic toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses","volume":"89","author":"Goff","year":"2015","journal-title":"J. Virol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/4\/386\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:13:46Z","timestamp":1760174026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/4\/386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,31]]},"references-count":91,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["v12040386"],"URL":"https:\/\/doi.org\/10.3390\/v12040386","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,31]]}}}